calcium leucovorin

DRUG2 trials

Sponsors

Celgene, University of Nebraska

Conditions

Adenocarcinoma of the PancreasMetastatic Pancreas AdenocarcinomaPancreas Cancer

Phase 1

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

CompletedNCT02620800

CelgeneMetastatic Pancreas Adenocarcinoma

Start: 2016-01-18End: 2018-10-29Updated: 2019-10-22

Phase 2

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

TerminatedNCT04141995

University of NebraskaAdenocarcinoma of the Pancreas, Pancreas Cancer

Start: 2021-02-12End: 2025-05-13Updated: 2025-08-07

Related Papers

Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results

Annals of Oncology2018-06-011 citations